Seeking Alpha

Hugan tablet sales temporarily halted

  • The China Food and Drug Administration halts the sale of Tianyin Pharmaceuticals' (TPI +3.1%) liver drug Hugan as it performs due diligence on its price and GMP before awarding the firm the right to sell the product in Zhejiang province. The agency's action is a customary part of its regulatory process.
  • The product contributes ~$600K in annual sales.
  • The company expects the examination to be over in April and sales will recommence.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs